|
1
|
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.
|
J Am Soc Nephrol
|
2007
|
4.59
|
|
2
|
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
|
J Urol
|
2010
|
2.54
|
|
3
|
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT.
|
BMC Immunol
|
2005
|
2.31
|
|
4
|
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
|
J Urol
|
2005
|
2.24
|
|
5
|
Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.
|
Cancer
|
2011
|
1.70
|
|
6
|
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.
|
J Urol
|
2009
|
1.68
|
|
7
|
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
|
J Urol
|
2008
|
1.66
|
|
8
|
Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.63
|
|
9
|
Validation of biomarker-based risk prediction models.
|
Clin Cancer Res
|
2008
|
1.57
|
|
10
|
Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening.
|
Urology
|
2010
|
1.53
|
|
11
|
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome.
|
Cancer
|
2013
|
1.52
|
|
12
|
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
|
J Urol
|
2008
|
1.49
|
|
13
|
Screening for prostate cancer.
|
CA Cancer J Clin
|
2009
|
1.48
|
|
14
|
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.
|
Blood
|
2006
|
1.46
|
|
15
|
Chilling outweighs photoperiod in preventing precocious spring development.
|
Glob Chang Biol
|
2013
|
1.43
|
|
16
|
Real-time individual predictions of prostate cancer recurrence using joint models.
|
Biometrics
|
2013
|
1.38
|
|
17
|
Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence.
|
J Natl Cancer Inst
|
2007
|
1.15
|
|
18
|
Prostate-specific antigen in the early detection of prostate cancer.
|
CMAJ
|
2007
|
1.13
|
|
19
|
Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis.
|
J Am Stat Assoc
|
2008
|
1.10
|
|
20
|
Association of the MC4R V103I polymorphism with the metabolic syndrome: the KORA Study.
|
Obesity (Silver Spring)
|
2008
|
1.06
|
|
21
|
Optimism, perceived risk of breast cancer, and cancer worry among a community-based sample of women.
|
Health Psychol
|
2004
|
1.01
|
|
22
|
Association analysis of frost tolerance in rye using candidate genes and phenotypic data from controlled, semi-controlled, and field phenotyping platforms.
|
BMC Plant Biol
|
2011
|
0.96
|
|
23
|
Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer.
|
J Urol
|
2007
|
0.95
|
|
24
|
Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United States.
|
Calcif Tissue Int
|
2008
|
0.92
|
|
25
|
The benefits of risk assessment tools for prostate cancer.
|
Eur Urol
|
2011
|
0.82
|
|
26
|
Recruiting patients with breast cancer and their families to behavioral research in the post-HIPAA period.
|
Oncol Nurs Forum
|
2007
|
0.82
|
|
27
|
Temporal changes in the clinical approach to diagnosing prostate cancer.
|
J Natl Cancer Inst Monogr
|
2012
|
0.80
|
|
28
|
Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies.
|
J Natl Cancer Inst
|
2007
|
0.79
|
|
29
|
Prostate cancer incidence and survival in immigrants to Sweden.
|
World J Urol
|
2013
|
0.78
|
|
30
|
The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.78
|
|
31
|
Prospective evaluation of health related quality of life for pediatric patients with ureteropelvic junction obstruction.
|
J Urol
|
2008
|
0.78
|
|
32
|
Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma.
|
J Natl Cancer Inst
|
2010
|
0.77
|
|
33
|
Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic white, Mexican-American, and African-American men.
|
Urology
|
2007
|
0.75
|
|
34
|
Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
|
J Natl Cancer Inst
|
2007
|
0.75
|
|
35
|
The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting.
|
Urol Oncol
|
2012
|
0.75
|
|
36
|
Prostate cancer detection: a view of the future.
|
Eur Urol
|
2010
|
0.75
|
|
37
|
Editorial for special issue on epidemiology and prevention of prostate cancer.
|
World J Urol
|
2012
|
0.75
|